|
|
Quote from Louis
Pasteur before he died
Although Louis Pasteur
discovered the germ theory of disease that states “…germs are the cause of disease,” note Dr. Pasteur's dying words:
"The germ is nothing,
the inner terrain is everything."
|
Why do I need Liver Support?
* The accumulation of chemicals in our body, from the water that we drink and bathe in, the air that we breathe,
and the food that we eat, have been
shown to weaken the immune system and
contribute to the development of various degenerative diseases. Double Blind Studies
have shown significant decreases in degenerative liver damage in patients with chronic liver disease (cirrhosis
of the liver) while using LIVER SUPPORT in as few as 30 days.
Recommended for those who:
* Suffer from Autoimmune Disorders
* Are Cancer Patients with poor Liver Function
* Are exposed to Environmental Toxins,
Chemicals or second hand smoke
* Consume Tobacco Products
* Have a history of liver
or gall bladder problems
* Have been taking medications/drugs
* Consume Alcohol
|
Double Blind Studies have shown significant decreases in degenerative liver
damage in patients with chronic liver disease (cirrhosis of the liver) while using LIVER SUPPORT.
Pharmaceutical Quality
FDA approved manufacturing plant and procedures
90 caplets
(artichoke-liver-detox):
|
|
2nd Double Blind Study
COMPARATIVE STUDY BETWEEN A COMPLEX OF
FLAVONOIDS AND POLYPHENOLS CREATED FROM
EXTRACTS OF ARTICHOKE AND SARSAPRILLA AND A
PLACEBO IN ALCOHOL RELATED LIVER DISEASE
DECEMBER 12, 1998
In a previous study, completed over two years ago in this same hospital, an extract of artichoke (Cynara Floridanum)
and sarsaparilla (Smilax Aristolochiaefolia) was evaluated in addressing the symptoms related to alcoholic liver
disease. This study was accomplished over a fifteen-day period with exceptional results. Because of these results
noted over a very short period of time, the hospital researchers were anxious to set up the same study over a longer
period (30 days). Please refer to the July 3, 1996, study for descriptions of symptoms and study parameters. Results
of this study are as follows:
ASCITES-
(accumulation of serous fluid in the spaces between tissues and organs
in the cavity of the abdomen)
A 72.38% reduction of the accumulation of serous abdominal fluid was noted in the treated group. The placebo saw
a 6.35% increase in abdominal fluid.
ENCEPHALOPATHY-
(a disease of the brain)
A 66.08% reduction of symptoms related to encephalopathy was noted in the treated
group. The placebo group saw a 12.24% increase in these symptoms.
HEPATOMEGALY
(enlargement of the liver)
The treated group experienced a 93.33% reduction in enlarged livers. In the placebo
group their livers continued to enlarge by another 7.14%.
SPLENOMEGALY
(enlargement of the spleen)
An 88.40% reduction in spleen enlargement was noted with the treated group. The placebo
group worsened by 11.54%.
WEAKNESS
The treated group noted a 73.64% increase in strength. There was a decrease in muscle
strength by 7.41% in the placebo group.
PERIPHERAL EDEMA
Edema in the extremities of the treated patients decreased by 48.21%. There was no
change in the placebo group.
HEMORRHAGES
The treated group noted a 100% decrease in capillary hemorrhaging in the skin, gums,
and nasal membranes. The placebo group saw an increase of 28.57% in hemorrhaging.
ANOREXIA
Loss of appetite decreased in the treated group by 76.98%. The placebo group noted
a decrease of 3.70%.
ABDOMINAL WALL VEINS
The treated group experienced a 60.62% decrease in tortuous veins in the abdomen
related to ascites. The placebo group saw a 3.33% decrease.
PALMAR ERYTHEMA
The treated group noted a 26.67% decrease in red and swollen palms. In the placebo
group there was no change.
TELANGIECTASIA
(dilatation of capillary vessels & arterioles
that often forms an angioma)
A 60.00% reduction in vascular lesions was noted in the treated group. A 3.33% reduction
was seen in the placebo group.
TOTAL BILIRUBIN
(a reddish yellow water insoluble pigment occurring especially in bile
and blood and causing jaundice if accumulated in excess)
The treated group noted a reduction of total bilirubin by 38.95%. The placebo group
increased by 5.68%.
ALKALINE PHOSPHATASE
(any of the phosphatases that are optimally active in alkaline medium and
occur in especially high concentrations in bone, the liver, the kidneys, and the placenta)
The treated group obtained 25.91% reduction in alkaline phosphates. There was an
11.69% increase in the placebo group.
SERUM GLUTAMIC OXALCETIC TRANSAMINASE (SGOT)
(an enzyme promoting transamination)
The treated group noted a decrease of 23.83% in SGOT levels. The placebo group experienced
a worsening of 11.71%.
PROTHROMBIN TIME
(a plasma protein produced in the liver in the presence of vitamin K
and converted into thrombin in the clotting of blood)
A 42.00% reduction in clotting time was noted with the treated group. An increase in clotting time was noted in
the placebo group of 6.60%.
SERUM ALBUMIN
(a crystallizable albumin or mixture of albumins that normally constitutes
more than half of the protein in blood serum and serves to maintain the osmotic pressure of the blood)
An increase of 37.27% in serum albumin was noted in the treated group. There was a decrease in the placebo group
of 1.95%.
GAMMA GLUTAMYL TRANSPEPTIDASE (GGT)
The treated group noted a reduction of 23.79% in GGT. The placebo group experienced
an increase of 9.92%
|
DR. CHARLES COCHRAN
1st Double Blind Study
INTERPRETATION OF RESULTS OBTAINED IN A DOUBLE BLIND TEST MADE IN THE GENERAL HOSPITAL MEXICO WITH THE PRODUCT
LIVER SUPPORT ON PATIENTS HAVING CHRONIC ALCOHOLIC HEPATIC DISEASE.
In order to analyze carefully the results of this study, it is necessary to know the importance of the two clinical
and laboratory parameters intervening in the calculations of Orrego and Maddrey Indexes.
We will compare the results of the parameters, the placebo control and the Liver Support groups on both indexes.
The results are presented as percentages of recovery and are obtained from the data obtained from each group of
30 patients, we will get an average of those results at the beginning and at the end of the study. Both averages
will give us a final recovery compared to the initial values. This way we may demonstrate the effectiveness of
Liver Support.
DEFINTIONS AND RESULTS OF PARAMETERS
ASCITES- Effusion and accumulation of serous fluid in the abdominal cavity. The experimental
group (Liver Support) experienced a 28.8% reduction of ascites while the placebo group experienced no change.
ENCEPHALOPATHY- a DEGENERATIVE DISEASE OF THE BRAIN.
Hepatic encephalopathy- a condition usually occurring secondarily to advanced disease of the liver. It is marked
by disturbances of consciousness that may progress to deep coma (hepatic coma), psychiatric changes of varying
degree, flapping tremor and fetor hepaticas. Also called portal-systemic encephalopathy. Patients on Liver Support
experienced a 34.55% reduction of hepatic encephalopathy. The placebo group experienced a 5.5% reduction.
SPLENOMEGALIA- Enlargement of the spleen. An 18.18%
reduction was observed in the Liver Support group and a 55% reduction was observed in the placebo group.
WEAKNESS- Lacking physical strength or vigor marked
by asthenia, atony, cardiasthena, enervation, fatigue and lassitude. The Liver Support group experienced an 83.45%
decrease in the incidence of weakness while the placebo group reported no change.
PERIPHERAL EDEMA- A condition in which the body tissues
contain an excess amount of fluid. The Liver Support Group experienced an 11.10% reduction in peripheral edema
while the placebo group had a 0.69% reduction.
HEMORRHAGES- Bleeding. This was one of the most important
benefits observed in the Liver Support group. The Liver Support group had an 89.41% reduction in hemorrhages while
the placebo had a 31% reduction.
ANOREXIA- Loss of appetite. Seen in depression, malaise,
commencement of fevers and illness, also in disorders of the alimentary tract, especially of the stomach, and as
a result of alcoholic excess and drug addiction. Anorexia was diminished by 86.07% in the Liver Support group.
There was no change in the placebo group.
TOTAL BILIRUBIN LEVEL - The predominant pigment of human
bile. Total serum bilirubin may be increased in cirrhosis of the liver and acute viral hepatitis. The Liver Support
group obtained 25.11% reduction in bilirubin, whereas the placebo group had a 7.2% increase.
OGT - (Oxalacetic Glutamic Transaminase). It is distributed
all over body tissue, especially in the heart and liver. Fewer amounts are found in the spleen, pancreas, kidneys,
lungs and brain. Any lesion of a tissue leads to the secretion of this enzyme to the blood stream. The activity
of OGT is risen under hepatic necrosis, cirrhosis of the liver or hepatic metastasis. In those patients who received
Liver Support this level diminished 22.56% in only 15 days of treatment and in the placebo group it diminished
8.51%.
PROTHROMBINE TIME - A test of clotting time made by determining the time for clotting
to occur after thromboplastin and calcium are added to decalcified plasma. There was 30.82% reduction in prothrombin
time for Liver Support patients, whereas the placebo group's time increased 1.25%. This is very important data,
because it means that Liver Support helps the healing of wounds faster.
SERUM ALBUMIN - One of a group of simple proteins widely distributed in tissues.
Albumin is a constituent of blood. Low levels of albumin in blood plasma are associated with a pathologic condition
of the liver. The Liver Support group experienced an increase of 8.85% of total albumin levels while the placebo
group experienced a 5.35% increase.
Liver Support System Ingredient Rationale
A proprietary blend of artichoke (Cynara Floridanum) and sarsaparilla (Smilax Aristolochiaefolia) that contains
the following naturally occurring bioflavonoids and polyphenols: silymarin, quercetin, catechin, hesperidin, rutin,
cynarin, and chlorogenic acid. Bioflavonoids are a class of water-soluble plant pigments (colors) that have anti-inflammatory,
antihistaminic and anti-viral properties. Health professionals formulated The Liver Support System specifically
for detoxifying the liver and gall bladder and supporting each of their functions.
Included Bioflavonoids
1. Silymarin
Numerous clinical studies have shown silymarin to be among the most powerful natural agents available for the prevention
and treatment of liver damage caused by exposure to human-made chemicals including alcohol induced liver degeneration
and cirrhosis.
References:
Wagner, H., "Antihepatotoxic flavonoids" in Cody, V., Middleton, E., and Harbourne, J.B., (eds.) Plant
Flavonoids in Biology and Medicine: Biochemical, Pharmacological, and Structure-Activity Relationships, Alan R.
Liss. New York, NY, 1986: pp. 545-58.
Salmi, H.A. and Sarna, S. "Effect of Silymarin on chemical, functional, and morphological alterations of the
liver. A double-blind controlled study." Scand J Gastroentrol., 1982, 17: pp.417-21.
Boari, C., Montanari, M., Galleti, G.P., et al. "Occupational toxic liver diseases. Therapeutic effects of
silymarin." Life Sci, 1981, 29: pp. 2,751-5.
2. Quercetin
Quercetin is a bioflavonoid with antioxidant effects. It is used for the prevention of atherosclerosis, hypercholesterolemia
(excess cholesterol in the blood), and coronary heart disease. It can inhibit carcinogenesis and reduce capillary
fragility. Quercetin is used extensively in the treatment of athletic injuries because it relieves pain and bruising
and acts synergistically with Vitamin C to protect and preserve the structure of capillaries. It also promotes
circulation, lowers cholesterol levels and treats and prevents cataracts. Quercetin fights cancer, diabetes, capillary
fragility, and arthritis; stabilizes membranes; protects against heart disease and allergies; normalizes blood
pressure; helps lowers cholesterol; and slows aging.
References:
Lininger, SW, et al. The Natural Pharmacy. 1st ed. Rocklin, CA: Prima Publishing; 1998.
Lean ME, Noroozi M, Kelly I. "Dietary flavonols protect diabetic human lymphocytes against oxidative damage
to DNA." Diabetes, (Jan. 1999), 48(1): 176-81.
Encyclopedia of Nutritional Supplements. Prima Publishing, Michael T. Murray, ND, 1996: pp. 324-5.
Satvric, B. "Quercetin in our diet: from potent mutagen to probable anticarcinogen." Clin Biochem 27,
1994: pp.245-8.
Ferrandiz, M.L. and Alcaraz, M.J. "Anti-inflammatory activity and inhibition of arachidonic acid metabolism
by flavonoids." Agents Action 32, 1991: pp.238-287.
3. Catechin
Catechin, another naturally occurring flavonoid, is similar in effect to silymarin. Catechin is a powerful anti-oxidant
that helps prevent free radical oxidative damage to cells. It also helps in the treatment and prevention of alcohol
and chemical-induced liver disease or damage. Catechin is also valuable for its ability to neutralize intestinal
toxins and assist in the stabilization of cell membranes.
Reference:
Golan, R. Optimal Wellness. Ballantine Publishing, 1995. P. 179.
4. Hesperidin
Hesperidin has been shown to be useful in clinical trials as an analgesic and anti-inflammatory.
Reference:
E.M. Galati, et al. "Biological effects of hesperidin, a citrus flavonoid. (Note 1): Anti-inflammatory and
analgesic activity." Farmaco 40 (11), Nov. 1994: pp. 709-12.
Null, G. "Clinician's Handbook of Natural Healing." Kensington Publications, 1997: pp. 170-71.
5. Rutin
A antioxidant bioflavonoid, free radical scavenger, and an iron-chelator. It is used as a vascular protector for
reducing capillary fragility, permeability, and bleeding; as a treatment for varicose vein symptoms; and as preventive
for stroke (the sudden rupture or clotting/blockage of a blood vessel to the brain). Some studies show that Rutin
offers protection from damage induced by asbestos, the cytotoxic effects of oxidized low-density lipoproteins (LDL),
and gastric injury from ethanol. It also offers some protection against DNA damage caused by hepatocarcinogens.
Rutin is used extensively in the treatment of athletic injuries because it relieves pain and bruises and acts synergistically
with Vitamin C to protect and preserve the structure of capillaries. It also promotes circulation, lowers cholesterol
levels, and treats and prevents cataracts.
Reference:
Kostyuk, V. and Potapovich, A. "Antiradical and chelating effects in flavonoid protection against silica-induced
cell injury." Arch Biochem Biophys, 355(1), 1998: 43-48.
Schmitt, A., Salvayre, R., Delchambre, J., and Negre-Salvayre, A. "Prevention by alpha-tocopherol and rutin
of glutathione and ATP depletion induced by oxidized LDL in cultured endothelial cells." Br J Pharmacol, 116(3),
1995: 1985-1990.
C Balch, James F., and Balch, Phyllis A. Prescription for Nutritional Healing. Avery Publishing Group, Garden City
Park, NY. 1997: 20.
6. Cynarin
Cynarin assists in the detoxification of the liver and gall bladder. It also supports the function of these two
important organs while and assists in their regeneration following damage. Cynarin stimulates the clearance of
bile from the liver, preventing congestion in the liver and thus diminishing the chances of liver damage.
Reference:
A. Encyclopedia of Nutritional Supplements. Prima Publishing, Michael T. Murray, ND, 1996: p. 353.
7. Sarsaparilla
Sarsaparilla has been used in the treatment of the following conditions: gout, arthritis, digestive disorders,
skin diseases, and cancer. Sarsaparilla contains saponins, which are steroid-like agents that bind with toxins
in the digestive tract. Historically, sarsaparilla has been used as a 'blood purifier' and a general tonic for
diseases associated with increased endotoxin levels, including arthritis, intestinal ulcerative conditions, eczema,
and psoriasis.
The tonic effect of sarsaparilla is the result of its ability to stimulate the removal of accumulated waste products
from the cells, blood, and lymph. These actions tend to increase the health of the entire body and increase vitality,
thereby increasing energy and endurance.
Reference:
The Natural Pharmacy. Prima Publishing, Liniger, Wright, Austin, Brown & Gaby, 1998: pp. 305-6.
Herbal Tonic Therapies. Keats Publishing, Mowrey, D., 1993: p. 354.
8. Chlorogenic Acid (16%)
Chlorogenic Acid is a naturally occurring, water soluble, phenolic acid that is a potent anti-oxidant, carcinogenic
inhibitor and protector against lipid peroxidation and free radical mediated cell injury.
Reference:
J Chromatogram A 1996; 741(2): pp.223-31
Biosci Biotechnol Biochem 1996; 60 (5): pp. 765-68.
Biochem Pharmacol 1987; 36 (5): pp.717-20.
Plant Foods Hum Nutr 1994; 45 (3): pp.287-98.
|
